Barclays Reiterates Overweight Rating on Jazz Pharmaceuticals plc (JAZZ)

Market Context

Jazz Pharmaceuticals plc operates in the Healthcare sector. The stock currently trades at $236.70 with a market capitalization of $10.0B. The stock has gained 76.9% over the past 52 weeks.

Analyst coverage from Barclays provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Jazz Pharmaceuticals plc.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Jazz Pharmaceuticals plc

Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jul 14, 2026	Wells Fargo	Overweight	N/A
Jul 14, 2026	Barclays	Overweight	N/A
Jul 09, 2026	Deutsche Bank	Buy	N/A
Jul 07, 2026	Truist Securities	Buy	N/A
Jun 10, 2026	B of A Securities	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View JAZZ Stock Page